Analysts Set Drägerwerk AG & Co. KGaA (ETR:DRW3) Target Price at €84.44

Drägerwerk AG & Co. KGaA (ETR:DRW3) has earned an average rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is €81.24 ($92.32).

Several research firms recently issued reports on DRW3. Kepler Capital Markets set a €71.00 ($80.68) target price on shares of Drägerwerk AG & Co. KGaA in a report on Wednesday. Warburg Research set a €88.70 ($100.80) target price on shares of Drägerwerk AG & Co. KGaA in a report on Wednesday. Finally, Nord/LB set a €72.00 ($81.82) target price on shares of Drägerwerk AG & Co. KGaA in a report on Thursday.

Drägerwerk AG & Co. KGaA stock traded down €8.10 ($9.20) during midday trading on Thursday, hitting €59.40 ($67.50). The stock had a trading volume of 315,370 shares, compared to its average volume of 33,804. The firm’s fifty day moving average is €69.50 and its two-hundred day moving average is €73.49. The company has a market capitalization of $603.50 million and a PE ratio of 4.97. Drägerwerk AG & Co. KGaA has a 52-week low of €60.70 ($68.98) and a 52-week high of €82.70 ($93.98). The company has a current ratio of 2.17, a quick ratio of 1.29 and a debt-to-equity ratio of 17.78.

About Drägerwerk AG & Co. KGaA

Drägerwerk AG & Co KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care.

Featured Article: Trading Ex-Dividend

Analyst Recommendations for Drägerwerk AG & Co. KGaA (ETR:DRW3)

Receive News & Ratings for Drägerwerk AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drägerwerk AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.